BDRX: Biodexa Pharmaceuticals Plc Financial Statements
Balance sheet, income statement, and cash flow statements for Biodexa Pharmaceuticals Plc (BDRX).
$1.47M Market Cap.
BDRX Market Cap. (MRY)
BDRX Shares Outstanding (MRY)
BDRX Assets (MRY)
Total Assets
$14.78M
Total Liabilities
$6.46M
Total Investments
$0
BDRX Income (MRY)
Revenue
$0
Net Income
-$5.73M
Operating Expense
$9.20M
BDRX Cash Flow (MRY)
CF Operations
-$12.39M
CF Investing
-$598.00K
CF Financing
$8.56M
BDRX Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Total Assets | $14,780,000 (40.20%) | $10,542,000 (90.81%) | $5,525,000 (-57.21%) | $12,913,000 (31.54%) |
Assets Current | $8,810,000 (25.32%) | $7,030,000 (49.96%) | $4,688,000 (-60.14%) | $11,761,000 (26.80%) |
Assets Non-Current | $5,970,000 (69.99%) | $3,512,000 (319.59%) | $837,000 (-27.34%) | $1,152,000 (112.55%) |
Goodwill & Intangible Assets | $5,646,000 (91.98%) | $2,941,000 (48916.67%) | $6,000 (0%) | $0 (0%) |
Shareholders Equity | $8,322,000 (77.90%) | $4,678,000 (47.94%) | $3,162,000 (-69.75%) | $10,452,000 (55.58%) |
Property Plant & Equipment Net | $324,000 (-43.26%) | $571,000 (-31.29%) | $831,000 (-27.86%) | $1,152,000 (112.55%) |
Cash & Equivalents | $1,669,000 (-72.05%) | $5,971,000 (110.54%) | $2,836,000 (-71.80%) | $10,057,000 (33.28%) |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $6,568,000 (931.08%) | $637,000 (-36.68%) | $1,006,000 (-2.71%) | $1,034,000 (80.77%) |
Trade & Non-Trade Payables | $3,504,000 (182.58%) | $1,240,000 (-14.31%) | $1,447,000 (32.51%) | $1,092,000 (-11.22%) |
Accumulated Retained Earnings (Deficit) | -$150,424,000 (-3.91%) | -$144,767,000 (-6.97%) | -$135,336,000 (-5.89%) | -$127,803,000 (-4.39%) |
Tax Assets | $573,000 (35.78%) | $422,000 (-50.12%) | $846,000 (26.27%) | $670,000 (-42.09%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $727,000 (56.68%) | $464,000 (-25.64%) | $624,000 (-18.54%) | $766,000 (194.62%) |
Debt Current | $609,000 (260.36%) | $169,000 (4.97%) | $161,000 (10.27%) | $146,000 (-27.00%) |
Debt Non-Current | $118,000 (-60.00%) | $295,000 (-36.29%) | $463,000 (-25.32%) | $620,000 (933.33%) |
Total Liabilities | $6,458,000 (10.13%) | $5,864,000 (148.16%) | $2,363,000 (-3.98%) | $2,461,000 (-20.59%) |
Liabilities Current | $5,034,000 (-9.61%) | $5,569,000 (193.11%) | $1,900,000 (3.20%) | $1,841,000 (-38.41%) |
Liabilities Non-Current | $1,424,000 (382.71%) | $295,000 (-36.29%) | $463,000 (-25.32%) | $620,000 (463.64%) |
BDRX Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Revenues | $0 (0%) | $381,000 (-45.49%) | $699,000 (20.93%) | $578,000 (68.51%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $3,793,000 (-12.64%) | $4,342,000 (-4.40%) | $4,542,000 (54.18%) | $2,946,000 (-40.58%) |
Research & Development Expense | $5,437,000 (33.69%) | $4,067,000 (-20.43%) | $5,111,000 (9.82%) | $4,654,000 (-23.30%) |
Operating Expenses | $9,199,000 (9.58%) | $8,395,000 (-12.83%) | $9,631,000 (27.13%) | $7,576,000 (-67.60%) |
Interest Expense | $165,000 (302.44%) | $41,000 (-22.64%) | $53,000 (20.45%) | $44,000 (-89.79%) |
Income Tax Expense | -$250,000 (38.42%) | -$406,000 (51.20%) | -$832,000 (-28.79%) | -$646,000 (49.57%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$5,729,000 (19.07%) | -$7,079,000 (7.54%) | -$7,656,000 (-40.22%) | -$5,460,000 (75.39%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$5,729,000 (19.07%) | -$7,079,000 (7.54%) | -$7,656,000 (-40.22%) | -$5,460,000 (75.39%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$5,729,000 (19.07%) | -$7,079,000 (7.54%) | -$7,656,000 (-40.22%) | -$5,460,000 (75.39%) |
Weighted Average Shares | $3,626,112,922 (1204.49%) | $277,971,722 (5544.47%) | $4,924,671 (56.16%) | $3,153,693 (131.18%) |
Weighted Average Shares Diluted | - | - | - | - |
Earning Before Interest & Taxes (EBIT) | -$5,814,000 (21.90%) | -$7,444,000 (11.75%) | -$8,435,000 (-39.15%) | -$6,062,000 (73.69%) |
Gross Profit | $0 (0%) | $381,000 (-45.49%) | $699,000 (20.93%) | $578,000 (68.51%) |
Operating Income | -$9,199,000 (-14.79%) | -$8,014,000 (10.28%) | -$8,932,000 (-27.64%) | -$6,998,000 (69.63%) |
BDRX Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Net Cash Flow from Investing | -$598,000 (-125.66%) | -$265,000 (-20.45%) | -$220,000 (20.86%) | -$278,000 (-110.80%) |
Net Cash Flow from Financing | $8,557,000 (-16.32%) | $10,226,000 (21657.45%) | $47,000 (-99.47%) | $8,805,000 (185.51%) |
Net Cash Flow from Operations | -$12,390,000 (-61.52%) | -$7,671,000 (0.71%) | -$7,726,000 (-7.83%) | -$7,165,000 (36.34%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$4,302,000 (-237.22%) | $3,135,000 (143.42%) | -$7,221,000 (-386.66%) | $2,519,000 (169.15%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | -$79,000 (61.84%) | -$207,000 (0%) | $0 (0%) |
Capital Expenditure | -$774,000 (-198.84%) | -$259,000 (-516.67%) | -$42,000 (84.89%) | -$278,000 (-321.21%) |
Issuance (Repayment) of Debt Securities | $245,000 (230.32%) | -$188,000 (-5.62%) | -$178,000 (17.21%) | -$215,000 (96.66%) |
Issuance (Purchase) of Equity Shares | $8,312,000 (-20.28%) | $10,427,000 (4190.95%) | $243,000 (-97.31%) | $9,035,000 (-7.26%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 | - |
Effect of Exchange Rate Changes on Cash | $0 (0%) | $0 (0%) | $0 (0%) | -$8,000 (-103.07%) |
Share Based Compensation | $283,000 (910.71%) | $28,000 (-77.24%) | $123,000 (38.20%) | $89,000 (122.03%) |
Depreciation Amortization & Accretion | $252,000 (-10.00%) | $280,000 (-17.65%) | $340,000 (-15.63%) | $403,000 (-66.61%) |
BDRX Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Gross Margin | - | 100.00% (0.00%) | 100.00% (0.00%) | 100.00% (0.00%) |
Profit Margin | - | -1858.00% (-69.63%) | -1095.30% (-15.95%) | -944.60% (85.40%) |
EBITDA Margin | - | -1880.30% (-62.36%) | -1158.10% (-18.28%) | -979.10% (84.62%) |
Return on Average Equity (ROAE) | -88.10% (51.22%) | -180.60% (-60.53%) | -112.50% (-76.89%) | -63.60% (62.34%) |
Return on Average Assets (ROAA) | -45.20% (48.69%) | -88.10% (-6.14%) | -83.00% (-72.92%) | -48.00% (55.96%) |
Return on Sales (ROS) | - | -1953.80% (-61.91%) | -1206.70% (-15.06%) | -1048.80% (84.39%) |
Return on Invested Capital (ROIC) | 3668.10% (409.53%) | 719.90% (236.04%) | -529.20% (42.25%) | -916.40% (-50.06%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) |
Price to Earnings Ratio (P/E) | -32.4 (-22.43%) | -26.46 (37.28%) | -42.2 (-1721.93%) | -2.32 (95.61%) |
Price to Sales Ratio (P/S) | - | 3.86 (-16.19%) | 4.61 (-73.19%) | 17.19 (-20.86%) |
Price to Book Ratio (P/B) | 0.14 (-55.24%) | 0.32 (-69.09%) | 1.02 (7.26%) | 0.95 (-14.34%) |
Debt to Equity Ratio (D/E) | 0.78 (-38.12%) | 1.25 (67.87%) | 0.75 (217.87%) | 0.23 (-49.02%) |
Earnings Per Share (EPS) | -1 (95.00%) | -20 (98.71%) | -1,550 (98.86%) | -136,000 (-1212.74%) |
Sales Per Share (SPS) | 0 (0%) | 173.5 (-98.99%) | 17,101.01 (-30.02%) | 24,436.96 (-29.05%) |
Free Cash Flow Per Share (FCFPS) | -363.03 (87.27%) | -2,852.81 (98.19%) | -157,736.44 (33.17%) | -236,009.05 (71.56%) |
Book Value Per Share (BVPS) | 229.5 (-86.36%) | 1,682.9 (-97.38%) | 64,207.34 (-80.63%) | 331,421.01 (-32.70%) |
Tangible Assets Book Value Per Share (TABVPS) | 251.9 (-90.79%) | 2,734.45 (-97.56%) | 112,068.41 (-72.63%) | 409,456.52 (-43.10%) |
Enterprise Value Over EBIT (EV/EBIT) | 1 (0%) | 0 (0%) | 0 (0%) | -1 (0%) |
Enterprise Value Over EBITDA (EV/EBITDA) | 0.67 (61.39%) | 0.42 (56.18%) | 0.27 (123.61%) | -1.13 (-269.61%) |
Asset Turnover | 0 (0%) | 0.05 (-38.16%) | 0.08 (49.02%) | 0.05 (200.00%) |
Current Ratio | 1.75 (38.67%) | 1.26 (-48.84%) | 2.47 (-61.38%) | 6.39 (105.87%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$13,164,000 (-66.00%) | -$7,930,000 (-2.09%) | -$7,768,000 (-4.37%) | -$7,443,000 (34.25%) |
Enterprise Value (EV) | -$4,680,108 (-23.82%) | -$3,779,758 (-44.93%) | -$2,607,996 (-130.56%) | $8,534,398 (-6.69%) |
Earnings Before Tax (EBT) | -$5,979,000 (20.12%) | -$7,485,000 (11.82%) | -$8,488,000 (-39.01%) | -$6,106,000 (73.98%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$5,562,000 (22.36%) | -$7,164,000 (11.50%) | -$8,095,000 (-43.05%) | -$5,659,000 (74.08%) |
Invested Capital | $3,158,000 (190.88%) | -$3,475,000 (-346.98%) | $1,407,000 (-21.00%) | $1,781,000 (488.86%) |
Working Capital | $3,776,000 (158.45%) | $1,461,000 (-47.60%) | $2,788,000 (-71.90%) | $9,920,000 (57.81%) |
Tangible Asset Value | $9,134,000 (20.17%) | $7,601,000 (37.72%) | $5,519,000 (-57.26%) | $12,913,000 (31.54%) |
Market Capitalization | $1,468,576 (-21.15%) | $1,862,411 (-52.01%) | $3,880,640 (-70.70%) | $13,245,509 (29.81%) |
Average Equity | $6,500,000 (65.82%) | $3,920,000 (-42.41%) | $6,807,000 (-20.71%) | $8,585,000 (-34.66%) |
Average Assets | $12,661,000 (57.60%) | $8,033,500 (-12.86%) | $9,219,000 (-18.88%) | $11,365,000 (-44.17%) |
Invested Capital Average | -$158,500 (84.67%) | -$1,034,000 (-164.87%) | $1,594,000 (140.97%) | $661,500 (-82.47%) |
Shares | 3,626,112,922 (1204.49%) | 277,971,722 (5544.47%) | 4,924,671 (56.16%) | 3,153,693 (131.18%) |